Pipeline Insight: Antithrombotics - Reaching the untreated prophylaxis market

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2007-04-09

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Novel oral anticoagulants and antiplatelet agents will have a profound impact on the antithrombotics market. Datamonitor expects Bayer's rivaroxaban and Sankyo/Eli Lilly's prasugrel to achieve blockbuster status. Parenteral anticoagulants are not expected to be large revenue generators, due to low clinical unmet need in this market segment and strong competition from current gold standard agents.


Scope

  • Event-driven sales projections for 2007-16 for key late-stage developmental antithrombotics in the seven major markets
  • Commercial analysis of late-stage developmental compounds in terms of their ability to satisfy unmet clinical needs
  • An overview of the antithrombotics R&D pipeline with a comprehensive assessment of all classes in development
  • Analysis of the potential for developmental antithrombotics with respect to the patient populations for which they are indicated


    • Report Highlights
    Following the abrupt withdrawal of AstraZeneca's Exanta in February 2006, Bayer Healthcare's rivaroxaban and Boehringer Ingelheim's Rendix are well positioned to profit from patients switching from warfarin, and market growth obtained by recruiting the previously untreated population.

    The highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents will be genericized within our forecast period. Consequently, pipeline agents are expected to become significant drivers in the market.

    Acute Coronary Syndrome is usually the first indication for which novel anticoagulants are approved; this is a quick route to market, while drug companies then prepare to launch their products in more lucrative, chronic treatment markets.


    Reasons to Purchase

  • Understand the factors that will drive the success of next-generation antithrombotics
  • Overcome the barriers to entry generated by lifecycle strategies of key players in the market
  • Assess the remaining market opportunity, where established therapies and other developmental compounds fail to address key unmet clinical needs

    • Table of Contents

    Other users found this report page using the following search terms: antithrombotics anticoagulants thrombosis antithrombotics market sch530348 ticagrelor azd tanogitran prasugrel patent prophylaxis 9684

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.